TCR ligand potency differentially impacts PD-1 inhibitory effects on diverse signaling pathways

Area of Science:

• Immunology
• Cancer Biology
• Molecular Signaling

Background:

• Checkpoint blockade immunotherapy, particularly targeting PD-1 (programmed cell death protein 1), has transformed cancer treatment.
• A quantitative, mechanistic understanding of how inhibitory receptors like PD-1 impact T cell signaling pathways remains incomplete.
• Existing data on PD-1's inhibitory mechanisms in T cells show discrepancies.

Purpose of the Study:

• To quantitatively analyze PD-1-induced suppressive effects on T cell signaling pathways.
• To elucidate the specific signaling pathways affected by PD-1, distinguishing between TCR-only and TCR/CD28-dependent signals.
• To investigate the influence of PD-L1 and CD80 expression, and peptide ligand quality on PD-1-mediated inhibition.

Main Methods:

• Development and application of a fluorescent intracellular live multiplex signal transduction activity reporter (FILMSTAR) system.
• Utilizing antigen-presenting cells with varying PD-L1 and CD80 expression levels.
• Employing T cell receptor (TCR) ligands of distinct potencies to stimulate T cells.

Main Results:

• Identified specific signaling pathways exclusively triggered by TCR or requiring both TCR and CD28 co-stimulation.
• Demonstrated that PD-1-mediated inhibition predominantly targets TCR-linked signals.
• Showed PD-1 inhibition is highly sensitive to the quality of the peptide ligand presented.

Conclusions:

• PD-1 inhibition primarily affects TCR-dependent signaling in T cells.
• The potency of neoantigens is crucial for modulating the efficacy of PD-1-based checkpoint therapy.
• Findings help reconcile conflicting data regarding the site of PD-1 action within T cells.